David Baltimore Buys 19,610 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore acquired 19,610 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was purchased at an average price of $1.06 per share, for a total transaction of $20,786.60. Following the acquisition, the director now directly owns 22,169 shares in the company, valued at $23,499.14. This represents a 766.31 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Regulus Therapeutics Stock Performance

Shares of RGLS stock remained flat at $1.00 on Friday. The stock had a trading volume of 643,240 shares, compared to its average volume of 590,682. The company’s fifty day moving average price is $1.47 and its 200-day moving average price is $1.55. The stock has a market cap of $65.50 million, a price-to-earnings ratio of -0.93 and a beta of 1.60. Regulus Therapeutics Inc. has a 12 month low of $0.83 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). As a group, analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of RGLS. Creative Planning purchased a new position in shares of Regulus Therapeutics during the third quarter valued at about $26,000. SG Americas Securities LLC bought a new stake in shares of Regulus Therapeutics in the 3rd quarter worth about $33,000. Jane Street Group LLC purchased a new stake in Regulus Therapeutics in the 3rd quarter valued at about $46,000. JPMorgan Chase & Co. lifted its position in Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, Barclays PLC increased its stake in Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 62,549 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.